Efficacy and Safety of Subclinical Sensitization with Diphenylcyclopropenone in Children with Alopecia Areata: A Retrospective Study / 대한피부과학회지
Korean Journal of Dermatology
;
: 371-377, 2022.
Article
in English
| WPRIM
| ID: wpr-938500
ABSTRACT
Background@#Contact immunotherapy with diphenylcyclopropenone is one of the first-line treatments for extensive alopecia areata, despite its adverse effects (AEs). @*Objective@#This study aimed to investigate whether a modified contact immunotherapy treatment protocol can safely promote hair regrowth in children. @*Methods@#Children with alopecia areata who were treated with modified contact immunotherapy with diphenylcyclopropenone were retrospectively reviewed. All patients were sensitized with 0.1% diphenylcyclopropenone and began treatment at subsequent increasing concentrations. The efficacy, AEs, and demographic factors were evaluated. @*Results@#A total of 32 patients, aged 9 to 17 years (mean age, 14.6 years), were included in the study. The mean disease duration was 26.8 months. Ten (31.3%) and 11 patients (34.4%) showed complete and partial responses, respectively. No AEs were observed after the sensitization. During treatment, 13 patients (40.6%) did not experience any AEs. Sixteen patients (50.0%) showed mild to moderate pruritus, and only three patients (9.4%) had severe pruritus. However, all AEs were well controlled. @*Conclusion@#A modified diphenylcyclopropenone treatment protocol with subclinical sensitization could induce a favorable therapeutic response and fewer AEs in children.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
/
Observational study
Language:
English
Journal:
Korean Journal of Dermatology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS